<?xml version="1.0" encoding="UTF-8"?>
<p>To no surprise, drug repositioning has its challenges despite being an advantage over traditional de novo drug discovery. Drug patents can play a critical role in drug repositioning. “Composition of matter” is a compound patent protection, which protects the rights of whoever invents or discovers any new processes, machines or new compounds but not limited to new formulations, recipes or materials for 20 years [
 <xref rid="B112-viruses-12-01058" ref-type="bibr">112</xref>]. Hence, patenting in drug repositioning can be arduous, especially when the original indications have already been trademarked ahead of new competitors [
 <xref rid="B113-viruses-12-01058" ref-type="bibr">113</xref>]. There are many ways to approach the existing COM patent with drug repositioning. For instance, the company Zalicus in collaboration with Sanofi Aventis Paris developed Prednisporin, which combines two old drugs, glucocorticoid Prednisolone acetate and the immunosuppressant Cyclosporine A for the treatment of allergic conjunctivitis [
 <xref rid="B63-viruses-12-01058" ref-type="bibr">63</xref>]. 
</p>
